The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain

Abstract

Different studies point to the implication of the endocannabinoid system in multiple sclerosis (MS) and animal models of MS. The purpose of this study was to evaluate a possible association of MS with polymorphic markers at the CNR1 gene, encoding the cannabinoid 1 (CB₁) receptor. We have performed a genetic analysis of an AAT repeat microsatellite localized in the downstream region of the CNR1 gene, in two case—control groups of MS patients and healthy controls (HC) from Spain (Madrid and Bilbao). MS patients with primary progressive MS (PPMS) had more commonly long ((AAT) ≥₁₃) alleles and genotypes with a significant difference for genotype 7/8 in Madrid (p = 0.043) and in the sum of both groups (p = 0.016); short alleles were less frequently found in PPMS with a significant difference for allele 5 in the analysis of both groups together (p = 0.039). In patients with relapsing MS, no consistent differences in allele and genotype distribution were found. Disease severity and progression was unrelated to AAT repeat variations. In conclusion, long (AAT) ≥₁₃ CNR1 genotypes could behave as risk factors for PPMS.

Keywords

(AAT)n repeat CB1 receptor CNR1 gene microsatellite multiple sclerosis polymorphism

Get full access to this article

View all access options for this article.

References

Oksenberg JR , Baranzini SE , Sawcer S. , Hauser SL The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008 ; 9: 516-526.

Schmidt AL , Anderson LM Repetitive DNA elements as mediators of genomic change in response to environmental cues. Biol Rev Camb Philos Soc 2006; 81: 531-543.

Correa F. , Docagne F. , Mestre L. , et al. Cannabinoid system and neuroinflammation: implications for multiple sclerosis. Neuroimmunomodulation 2007; 14: 182-187.

Vettor R. , Pagotto U. , Pagano C. , Pasquali R. Here, there and everywhere: the endocannabinoid system. J Neuroendocrinol 2008; 20(Suppl 1): iv-vi.

Kano M. , Ohno-Shosaku T. , Hashimotodani Y. , Uchigashima M. , Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009; 89: 309-380.

Howlett AC , Barth F. , Bonner TI , et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.

Wilson RI , Nicoll RA Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses . Nature 2001; 410: 588-592.

Tsou K. , Brown S. , Sanudo-Pena MC , Mackie K. , Walker JM Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 393-411.

Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 2006; 46: 101-122.

10.

Matsuda LA , Lolait SJ , Brownstein MJ , Young AC , Bonner TI Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.

11.

Hoehe MR , Caenazzo L. , Martinez MM , et al. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol 1991 ; 3: 880-885.

12.

Zhang PW , Ishiguro H. , Ohtsuki T. , et al. Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with poly-substance abuse . Mol Psychiatry 2004; 9: 916-931.

13.

Comings DE , Muhleman D. , Gade R. , et al. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry 1997; 2: 161-168.

14.

Li YC , Korol AB , Fahima T. , Nevo E. Microsatellites within genes: structure, function, and evolution. Mol Biol Evol 2004; 21: 991-1007.

15.

Comings DE Polygenic inheritance and micro/minisatellites. Mol Psychiatry 1998; 3: 21-31.

16.

Li T. , Liu X. , Zhu ZH , et al. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 2000; 5: 128-130.

17.

Ballon N. , Leroy S. , Roy C. , et al. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J 2006; 6: 126-130.

18.

Covault J. , Gelernter J. , Kranzler H. Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence . Mol Psychiatry 2001; 6: 501-502.

19.

Barrero FJ , Ampuero I. , Morales B. , et al. Depression in Parkinson’s disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J 2005; 5: 135-141.

20.

Siegfried Z. , Kanyas K. , Latzer Y. , et al. Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/ purging subtypes. Am J Med Genet B Neuropsychiatr Genet 2004; 125B: 126-130.

21.

Muller TD , Reichwald K. , Bronner G. , et al. Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa. Child Adolesc Psychiatry Ment Health 2008; 2: 33.

22.

Gadzicki D. , Muller-Vahl KR , Heller D. , et al. Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene. Am J Med Genet B Neuropsychiatr Genet 2004; 127B: 97-103.

23.

Chavarria-Siles I. , Contreras-Rojas J. , Hare E. , et al. Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2008; 147: 279-284.

24.

Ujike H. , Takaki M. , Nakata K. , et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002; 7: 515-518.

25.

Martinez-Gras I. , Hoenicka J. , Ponce G. , et al. (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur Arch Psychiatry Clin Neurosci 2006; 256: 437-441.

26.

Tsai SJ , Wang YC , Hong CJ Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia . Psychiatr Genet 2000; 10: 149-151.

27.

Seifert J. , Ossege S. , Emrich HM , Schneider U. , Stuhrmann M. No association of CNR1 gene variations with susceptibility to schizophrenia . Neurosci Lett 2007; 426: 29-33.

28.

Pertwee RG Cannabinoids and multiple sclerosis. Neurosci Lett 2007; 36: 45-59.

29.

McDonald WI , Compston A. , Edan G. , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.

30.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.

31.

Roxburgh RH , Seaman SR , Masterman T. , et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.

32.

Guo SW , Thompson EA Performing the exact test of Hardy-Weinberg proportion for multiple alleles . Biometrics 1992; 48: 361-372.

33.

Gilbert GL , Kim HJ , Waataja JJ , Thayer SA Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity . Brain Res 2007; 1128: 61-69.

34.

Pryce G. , Ahmed Z. , Hankey DJ , et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003; 126: 2191-2202.

35.

Eljaschewitsch E. , Witting A. , Mawrin C. , et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells . Neuron 2006; 49: 67-79.

36.

Molina-Holgado E. , Vela JM , Arévalo-Martin A. , et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002; 22: 9742-9753.

37.

Berrendero F. , Sanchez A. , Cabranes A. , et al. Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 2001; 41: 195-202.

38.

Cabranes A. , Venderova K. , de Lago E. , et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 2005; 20: 207-217.

39.

Sanchez AJ , Gonzalez-Perez P. , Galve-Roperh I. , Garcia-Merino A. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4 -benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochem Pharmacol 2006; 72: 1697-1706.

40.

Fujiwara M. , Egashira N. New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. J Pharmacol Sci 2004; 96: 362-366.

41.

Baker D. , Pryce G. , Giovannoni G. , Thompson AJ The therapeutic potential of cannabis. Lancet Neurol 2003; 2: 291-298.

42.

Centonze D. , Bari M. , Rossi S. , et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007; 130: 2543-2553.

43.

Bauduer F. , Feingold J. , Lacombe D. The Basques: review of population genetics and Mendelian disorders. Hum Biol 2005; 77: 619-637.

44.

Woolmore JA , Stone MJ , Holley SL , et al. Polymorphisms of the cannabinoid 1 receptor gene and cognitive impairment in multiple sclerosis. Mult Scler 2008; 14: 177-182.